Professional Documents
Culture Documents
Seeking Alpha March 2010 Interview
Seeking Alpha March 2010 Interview
Game-Changing Strategy
Joel Smolen is a seasoned hedge fund manager, venture capitalist and chief executive who has
been creating value for clients and investors for over forty years. He is currently CEO of Axion
Capital Management, LLC and personally manages the Axion Opportunity Fund, which he founded
in 2001. Joel also sits on the Board of Directors for AmpliMed Corporation, a biotech drug discovery
company founded in 1989, which has multiple drugs in late phase clinical trials.
Joel was a pioneer in the metallurgy and emerging electronics industry, and consulted and worked
with Intel, Apple, IBM, AMD, and National Semiconductor in the 70’s and 80’s. He founded and was
CEO of Applied Molecular Technology Corporation, which was sold to Boliden AB, a billion-dollar
European metals company. Prior to that, Joel was founder and CEO of MicroMetallics Corporation,
which was sold to Xstrata PLC, (XTA.L) an international metals and mining company with over
20,000 employees in 2008. Joel was also Senior Vice President of LMC Corporation, now part of
Sims Metal Management (SMS), a worldwide metals company. Joel also created two business
parks, and built over a million feet of office space in the San Francisco Bay Area.
In 1999 Joel became a registered investment advisor and began concentrating on individual investor
and private equity investments.
Specialties
Investment opportunities in the technology, commodities, metals and energy, sectors, private equity
and wealth advisory services
http://seekingalpha.com/article/194546-high-conviction-a-brazilian-miner-with-a-game-changing-
strategy
Joel Smolen's Company
Axion Capital Management is a boutique asset management firm offering alternative investment opportunities
and wealth management services to institutions and high net worth individuals.
Our hedge fund, Axion Opportunity Fund, LP has consistently ranked at or near the top of the equity
opportunistic long/short and Global Macro classifications. In 2009, Axion Opportunity Fund, LP was ranked #1 in
class for compound annual return by BarclayHedge in the 1 year, 3 year and 5 year intervals, as well as over the life
of the Fund.
Besides managing an absolute return fund, Axion Capital Management also has extensive experience in the private
equity space. Over the years our firm has funded unique opportunities in technology and life sciences. Most
recently, we were the lead investor in AmpliMed Corporation, a privately-held oncology drug development
company, founded by renowned oncologists in 1989. The company currently has multiple pharmaceuticals in
various stages of drug development.
In addition, Axion Capital Management offers private wealth management services for high net worth individuals
seeking long term capital appreciation.
Email Address:smolen@axionfund.com
The Axion Report is a work in progress but we anticipate a rolling dialog concerning investment themes we are
following and issues which impact the market.
Visit http://www.theaxionreport.com/ »